OMEROS CORP Research and Development in Process
OMEROS CORP (OMER) reported Research and Development in Process of $10.89 million for the 207-month period ending 2011-09-30, per its 10-Q filed 2011-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2011-11-08
- OMEROS CORP research and development in process for the quarter ending 2011-09-30 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 204 month | Research and Development in Process 207 month |
|---|---|---|---|
| 2011-09-30 | $0.00 derived: 10-Q 207 month − 10-Q 204 month · filed 2011-11-08 | $10.89M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $10.89M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |